BRIBF (Brii Biosciences) Tax Expense: $0.27 Mil (TTM As of Dec. 2025)


BRIBF Brii Biosciences Ltd BRIBF
34 GF Score
Price $0.15
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences Tax Expense?

Brii Biosciences BRIBF 34 Tax Expense is $0.27 Mil as of Dec. 2025. GuruFocus rates BRIBF with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Brii Biosciences's tax expense for the months ended in Dec. 2025 was $0.27 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was $0.27 Mil.


Brii Biosciences  (OTCPK:BRIBF) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Brii Biosciences Tax Expense Related Terms


Brii Biosciences Tax Expense Historical Data

* Premium members only.

The historical data trend for Brii Biosciences's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brii Biosciences Tax Expense Chart

Brii Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.27

Brii Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.27
BRIBF
34GF Score
Brii Biosciences Ltd BRIBF
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.27 Mil mean?
Brii Biosciences (BRIBF) has a Tax Expense of $0.27 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Brii Biosciences and its competitors.
Is Brii Biosciences' Tax Expense too high?
Brii Biosciences' current Tax Expense is $0.27 Mil. Overall, Brii Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' Tax Expense compare to VRTX and REGN?
Brii Biosciences' Tax Expense of $0.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on Brii Biosciences and its competitors. Brii Biosciences's current Tax Expense is $0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (BRIBF) has a current Tax Expense of $0.27 Mil. The current Tax Expense is $0.27 Mil. Brii Biosciences' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For Brii Biosciences (BRIBF), the current Tax Expense is $0.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Other Exchanges 02137:Hong Kong7SS:Germany
Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
34GF Score

Get the complete analysis for BRIBF

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price